Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

Profusa initiates first commercial revenue with healthcare research offerings launch

Profusa (NASDAQ: PFSA) has announced the launch of its healthcare research version of its Lumee tissue oxygen monitoring into the contract research organizations (CRO) market, which is expected to generate immediate...

January 16, 2026

Developments

GT submits IND for GTB-5550 TriKE in solid tumors

GT Biopharma (NASDAQ: GTBP) has announced that it submitted an investigational new drug (IND) application to the FDA in December 2025 for GTB-5550 TriKE, a B7-H3-targeted natural killer (NK) cell engager for the...

January 15, 2026

Developments

Frontiers in Oncology to publish BioMark’s research on ML model for lung cancer detection

BioMark Diagnostics (CSE: BUX; FSE: 20B; OTCQB: BMKDF) has announced that the peer-reviewed journal Frontiers in Oncology has accepted for publication the company’s research on a machine learning (ML) predictive model...

January 15, 2026

Developments

Mount Sinai becomes first in NYC to deliver incision-free, MRI-guided prostate treatment with Profound’s TULSA-PRO

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that the world-renowned Mount Sinai Hospital, Metro New York (NYC), has successfully treated its first prostate cancer patient with the TULSA-PRO system. The TULSA...

January 15, 2026

Developments

cbdMD acquires Bluebird Botanicals

cbdMD (NYSE American: YCBD) has announced the strategic acquisition of closely held Bluebird Botanicals through an asset purchase comprised of an initial share issuance and earnout shares. According to cbdMD, the...

January 14, 2026

Developments

Clearmind achieves 100% treatment success in second cohort of CMND-100 trial in AUD

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the successful completion of treatment for all patients in the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100—the...

January 14, 2026

Developments

Cardiol achieves 50% enrollment milestone in Phase 3 MAVERIC recurrent pericarditis trial

Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) announced that it has surpassed 50% patient enrollment in MAVERIC, its Phase 3 randomized, double-blind, placebo-controlled, multi-center international trial evaluating...

January 13, 2026

Developments

Profound surpasses 2025 TULSA-PRO installed base goal

Profound Medical (NASDAQ:PROF; TSX:PRN) announced that its TULSA-PRO system installed base reached 78 as of December 31, 2025—exceeding its previously announced goal of 75 installs by year-end 2025. The company’s TULSA...

January 12, 2026

Developments

Nature Eye publishes positive Phase 1 results for Ocugen’s gene therapy

Ocugen (NASDAQ: OCGN) has announced the publication of positive Phase 1 GARDian1 trial results for OCU410ST, its novel modifier gene therapy for Stargardt disease, in the peer-reviewed journal Nature Eye, published by...

January 12, 2026

Developments

PharmaJet’s Needle-free Injection System selected for DNA immunotherapy in advanced melanoma

Closely held PharmaJet announced that its partner, Scancell, has reported updated Phase 2 clinical data from the SCOPE study in unresectable advanced melanoma demonstrating a progression-free survival (PFS) rate of 74%...

January 9, 2026

Developments

Autonomix highlights data showing pain relief observed in all stages of pancreatic cancer

Autonomix Medical (NASDAQ: AMIX) has announced new subgroup clinical data from its proof-of-concept study presented at the 2026 ASCO Gastrointestinal Cancers Symposium demonstrating rapid, durable, and meaningful pain...

January 9, 2026

Developments

Athira announces name change to LeonaBio with new ticker LONA

Athira Pharma (NASDAQ: ATHA) has announced that it has changed its name to LeonaBio (NASDAQ: LONA) effective January 12, 2026, to align with its acquisition of rights to develop and commercialize lasofoxifene, a late...

January 9, 2026

Developments

Day One acquires Mersana and expands pipeline

Day One Biopharmaceuticals (NASDAQ: DAWN) has announced the completion of all conditions of its tender offer to acquire all outstanding shares of Mersana Therapeutics (NASDAQ: MRSN) for $25 per share in cash plus one...

January 7, 2026

Developments

Actuate announces positive Phase 1 elraglusib results in pediatric cancer

Actuate Therapeutics (NASDAQ: ACTU) has announced results from the phase 1 portion of its Actuate-1902 Phase 1/2 clinical study evaluating elraglusib as a monotherapy or in combination with irinotecan, irinotecan plus...

January 7, 2026

Developments

YD Bio enters MOU to merge with EG BioMed

YD Bio (NASDAQ: YDES) has announced that it has entered into a Memorandum of Understanding (MOU) to merge with closely held EG BioMed—a biotechnology company specializing in DNA methylation–based cancer diagnostics and...

January 7, 2026

Developments

First patient dosed in Akebia’s Phase 2 trial of praliciguat in FSGS

Akebia Therapeutics (NASDAQ: AKBA) has announced that the first patient has been dosed in its Phase 2 clinical trial of praliciguat, an oral once-daily soluble guanylate cyclase stimulator being evaluated for the...

January 7, 2026

Developments

Johns Hopkins Medicine treats first commercial TULSA-PRO case; Profound marks major milestone as hospital launches iMRI suite to expand access to advanced prostate care

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that The Johns Hopkins Hospital has treated its first non-clinical-trial prostate cancer patient using the company’s TULSA-PRO system. The milestone marks the...

January 6, 2026

Developments

Polyrizon reports positive preclinical results of PL-14 vs HPMC

Polyrizon (NASDAQ: PLRZ) has announced new results from a preclinical study evaluating the allergen-blocking performance of its PL-14 Allergy Blocker formulation compared to hydroxypropyl methylcellulose (HPMC), an...

January 5, 2026

Developments

MetaVia reports positive results from Phase 1b trial of DA-1726 in metabolic disease

MetaVia (NASDAQ: MTVA) has announced positive, statistically significant results from the eight-week, non-titrated, 48 mg, multiple ascending dose (MAD) cohort of its Phase 1 clinical trial of DA-1726, a novel dual...

January 5, 2026

Developments

Hoth expands IP portfolio with filing of two patent applications

Hoth Therapeutics (NASDAQ: HOTH) has announced the filing of two U.S. provisional patent applications to expand its IP portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin...

January 5, 2026

Developments

Annovis launches OLE study in Parkinson’s disease

Annovis Bio (NYSE: ANVS) has announced it will begin an open-label extension (OLE) study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in Parkinson’s disease (PD) patients. The study aims...

December 19, 2025

Developments

Altimmune’s pemvidutide achieves key measures of success at 48 weeks in MASH trial

Altimmune (NASDAQ: ALT) has announced positive topline results from the IMPACT Phase 2b trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist, in patients with metabolic dysfunction-associated...

December 19, 2025

Subscribe